Evidence map›Paper›PMID 41725497›Full record

ArticleCNS neuroscience & therapeutics2026

Chidamide Is Screened to Suppress Epileptogenesis in Mice Models via Blocking Histone Deacetylase 1.

Qian Guo, Zhao-Jun Wang, Wei-Bo Dong, Li Pang, Xiao-Yuan Mao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Qian GuoDepartment of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics and National Clinical Research Center for Geriatric Disease (Xiangya Hospital), Xiangya Hospital Central South University, Changsha, China.
Zhao-Jun WangDepartment of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics and National Clinical Research Center for Geriatric Disease (Xiangya Hospital), Xiangya Hospital Central South University, Changsha, China.
Wei-Bo DongDepartment of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics and National Clinical Research Center for Geriatric Disease (Xiangya Hospital), Xiangya Hospital Central South University, Changsha, China.
Li PangDepartment of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics and National Clinical Research Center for Geriatric Disease (Xiangya Hospital), Xiangya Hospital Central South University, Changsha, China.
Xiao-Yuan MaoDepartment of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics and National Clinical Research Center for Geriatric Disease (Xiangya Hospital), Xiangya Hospital Central South University, Changsha, China.ORCID https://orcid.org/0000-0002-5149-1204

Funding

National Natural Science Foundation of China 82274027National Natural Science Foundation of China 82474014Natural Science Foundation of Hunan Province 2025JJ20087
6 · The paper itself

Abstract

aimsDisease-modifying and anti-epileptogenic therapies for epilepsy remain limited. Given the critical role of histone deacetylases (HDACs) in epileptogenesis, this study aimed to identify effective HDAC inhibitors and evaluate their anti-epileptogenic potential.

methodsA Mg

resultsChidamide (Chi) exhibited the most inhibitory effect among nine HDAC inhibitors. Chi significantly reduced seizure susceptibility in acute PTZ- and KA-induced models. In the chronic KA model, Chi attenuated SRS, improved neuronal survival, reduced MFS, and suppressed astrocytic and microglial activation. Chi markedly decreased hippocampal HDAC1 expression, while neuronal HDAC1 overexpression abolished its anti-epileptogenic effects.

conclusionChi attenuates epileptogenesis by inhibiting neuronal HDAC1 and may serve as a promising repurposed anti-epileptogenic therapy.

Indexed as

AnticonvulsantsBenzamidesEpilepsyHistone Deacetylase 1Histone Deacetylase InhibitorsAminopyridinesAnimalsDisease Models, AnimalKainic AcidMaleMiceMice, Inbred C57BLNeuronsPC12 CellsPentylenetetrazoleRatsAminopyridinesAnticonvulsantsBenzamidesHdac1 protein, mouseHistone Deacetylase 1Histone Deacetylase InhibitorsKainic AcidN-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamidePentylenetetrazolechidamideepilepsyepileptogenesishistone deacetylase 1

Identifiers

PMID41725497
PMCPMC12928038

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.